OR WAIT 15 SECS
- About Us
- Advertise
- Editorial Information
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Laureate to Manufacture Antibodies for Tolerx and Tolera
BioPharm International Editors
Laureate Pharma, Inc. (Princeton, NJ), has entered into contract manufacturing agreements with Tolerx, Inc. (Cambridge, MA), and Tolera Therapeutics, Inc. (Kalamazoo, MI).
Laureate Pharma, Inc. (Princeton, NJ), has entered into contract manufacturing agreements with Tolerx, Inc. (Cambridge, MA), and Tolera Therapeutics, Inc. (Kalamazoo, MI).
Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases. Laureate will produce Tolerx’s humanized anti-GITR antibody known as TRX518, which is currently in development for cancer and chronic viral indications. Details of the agreement were not disclosed.
Laureate has also entered into a cGMP contract manufacturing agreement with Tolera Therapeutics, a biotechnology company that develops and offers targeted therapies and solutions for immune modulation and related medical needs. According to the agreement, Laureate will produce Tolera’s TOL101 MAb under cGMP conditions to be used in clinical trials. Terms of the manufacturing agreement were not disclosed.
Related Content:
News